drugset / Trial / NCT02302846
Study of MLN9708 as Maintenance Therapy for Patients With Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS) in Remission
Phase 2
Terminated
5 enrolled
M.D. Anderson Cancer Center
Millennium: The Takeda Oncology Company · collab
NaSingle-groupOpen-labelTreatment
Summary
The goal of this clinical research study is to learn if ixazomib can prevent AML or MDS from coming back in patients who are in remission. The safety of this drug will also be studied.
Timeline
- Start
- 2015-03-20
- Primary completion
- 2017-05-30
- Completion
- 2017-05-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ixazomib | Unknown | 4 mg | Oral |